Exenatide Presentation Exenatide is a glp 1 agonist used in the management of type 2 diabetes mellitus. exenatide is a glucagon like peptide 1 (glp 1) analog 8. it activates the glp 1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control 8. Exenatide once weekly – in a noninferiority trial, 14,752 patients with type 2 diabetes (73.1 percent had previous cvd) were randomly assigned to receive subcutaneous exenatide or placebo once weekly . after a median follow up of 3.2 years, the primary endpoint (a composite of first occurrence of death from cardiovascular causes, nonfatal.
Exenatide Presentation Exenatide is fda indicated to improve glycemic control in adult patients with type 2 diabetes mellitus when used as an adjunct to diet and exercise. it is not recommended as first line therapy to treat diabetes. however, clinical trials have shown exenatide to be both safe and effective when used as monotherapy or in combination with other diabetic medications. Exenatide, the comparator treatment in this trial, is a synthetic form of the glp 1 ra exendin 4, which has 53% homology to native human glp 1 . when encapsulated in microspheres, exenatide is released slowly from the injection site (extended release [er]) and is therefore suitable for once weekly dosing . Clinical studies investigating the pharmacokinetics of exenatide qw show that plasma drug concentrations (50 pg ml) are sufficient for fg reduction after 2 weeks of exenatide 2 mg qw. steady state occurs after 6–7 weeks, and the compound can be measured in plasma at least 8.5 weeks after a single injection [25, 26]. Exenatide er has been encapsulated in 0.06 mm diameter microspheres of medical grade poly(d,l, lactide co glycolide). 22 following injection of a single dose, exenatide is released from the microspheres over approximately 10 weeks. 23 there is an initial period of release of surface bound exenatide, followed by a gradual release of exenatide.
Exenatide Presentation Clinical studies investigating the pharmacokinetics of exenatide qw show that plasma drug concentrations (50 pg ml) are sufficient for fg reduction after 2 weeks of exenatide 2 mg qw. steady state occurs after 6–7 weeks, and the compound can be measured in plasma at least 8.5 weeks after a single injection [25, 26]. Exenatide er has been encapsulated in 0.06 mm diameter microspheres of medical grade poly(d,l, lactide co glycolide). 22 following injection of a single dose, exenatide is released from the microspheres over approximately 10 weeks. 23 there is an initial period of release of surface bound exenatide, followed by a gradual release of exenatide. Case presentation. a 67 year old woman with t2dm presented to our institution with acute complaints of tongue swelling, difficulty breathing, dizziness and diffuse itching that began 15 min after self administering her first dose of exenatide er. Exenatide synthetic. for suspension, extended release; subcutaneous. two options: (1) one in vivo single dose bioequivalence study with pharmacokinetic endpoints in healthy subjects or (2) one in vivo multiple dose steady state bioequivalence study with pharmacokinetic endpoints in patients. the two options in this guidance are selective.
Exenatide Presentation Ppt Case presentation. a 67 year old woman with t2dm presented to our institution with acute complaints of tongue swelling, difficulty breathing, dizziness and diffuse itching that began 15 min after self administering her first dose of exenatide er. Exenatide synthetic. for suspension, extended release; subcutaneous. two options: (1) one in vivo single dose bioequivalence study with pharmacokinetic endpoints in healthy subjects or (2) one in vivo multiple dose steady state bioequivalence study with pharmacokinetic endpoints in patients. the two options in this guidance are selective.
Exenatide Presentation
Comments are closed.